Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors
2024

Bone Metastasis in Differentiated Thyroid Cancer: A Spanish Study

Sample size: 133 publication 10 minutes Evidence: moderate

Author Information

Author(s): Dueñas-Disotuar Suset, Piñar-Gutiérrez Ana, de Lara-Rodríguez Irene, Sastre-Marcos Julia, Anda-Apiñániz Emma, Oleaga-Alday Amelia, Galofré JC, Orois Aida, Alcázar-Lázaro Victoria, Martínez-Guasch Laia, Sánchez-Ragnarsson Cecilia, Gálvez-Moreno María Ángeles, Familiar-Casado Cristina, Martín-Hernández Tomás, Romero-Lluch Ana R.

Primary Institution: Department of Endocrinology, Hospital Universitario Virgen del Rocío, Sevilla, Spain

Hypothesis

What are the clinical characteristics, survival rates, and prognostic factors for patients with bone metastases from differentiated thyroid carcinoma?

Conclusion

Patients with differentiated thyroid carcinoma and bone metastases in Spain have a 5-year survival rate of 39.5% and a 10-year survival rate of 28.5%, with better outcomes associated with treatment using I131.

Supporting Evidence

  • 52.6% of patients had bone metastases at the initial diagnosis of differentiated thyroid carcinoma.
  • 39.5% of patients survived 5 years after diagnosis of bone metastases.
  • Patients treated with I131 had a better survival outcome.
  • 54.1% of patients in the study died during follow-up.
  • 66.2% of patients had metastases in other locations at initial diagnosis.

Takeaway

This study looked at patients with thyroid cancer that spread to their bones and found that those treated with a specific medicine had better chances of living longer.

Methodology

A multicenter retrospective observational study was conducted, analyzing data from patients diagnosed with differentiated thyroid carcinoma and bone metastases between 1980 and 2022.

Potential Biases

Variability in treatment protocols across different centers may introduce bias in interpreting results.

Limitations

The study's observational and retrospective nature and relatively small sample size limit the ability to establish clear prognostic factors.

Participant Demographics

The cohort included 57.1% women, with a median age of 67 years at diagnosis of bone metastases.

Statistical Information

P-Value

p=0.015 for age ≥67 years, p=0.048 for lymph node metastases, p=0.027 for I131 treatment

Confidence Interval

95% CI 1.005-2.098 for lymph node metastases, 95% CI 0.304-0.931 for I131 treatment, 95% CI 1.142-3.47 for age ≥67 years

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fendo.2024.1466245

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication